18 February 2021
Pfizer and BioNTech announced that the companies have signed an agreement with the European Commission (EC), the executive branch of the European Union (EU), to supply 200 million additional doses of their Covid-19 vaccine. The agreement brings the total supply of the vaccine to EU to 500 million doses; the EC can also exercise the option to request supply an additional 100 million doses of the vaccine.
The EC has procured an additional 150 million doses of Moderna’s Covid-19 vaccine, which is expected to be delivered in the third and fourth quarter of 2021. This brings the total confirmed order commitment to 310 million doses in 2021. As per the agreement, the European Commission can also exercise the option to procure an additional 150 million doses of the vaccine, which is expected to be delivered in 2022.
Spanish pharmaceutical company Pharma Mar has received regulatory approval to conduct a late-stage clinical trial in the UK of its drug Apildin to treat hospitalised patients with moderate Covid-19. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) is the first regulator to authorise the Neptuno trial, which will test the efficacy of the drug against other treatments for treating moderate Covid-19.
The US National Institutes of Health (NIH) has funded a new study called the IMPAACT 2032, which will analyse the effects of remdesivir in treating Covid-19 in pregnant women. The study is expected to be conducted across 17 sites in the continental US and Puerto Rico; it will aim to understand how pregnant women metabolise the drug and whether there are any potential risks.